FDA Grants Approval for First Chikungunya Virus Vaccine in the US
The U.S. Food and Drug Administration (FDA) has approved Ixchiq, the first vaccine for chikungunya virus, a mosquito-borne disease. The vaccine is approved for individuals aged 18 and older who are at increased risk of exposure to the virus. Chikungunya is a global health threat with millions of reported cases in the past 15 years. The most common symptoms include fever and joint pain, and some individuals may experience prolonged joint pain. Ixchiq is administered as a single dose injection and contains a weakened version of the virus. The vaccine's safety was evaluated in clinical studies, and the most commonly reported side effects were headache, fatigue, and muscle pain. The FDA is requiring a postmarketing study to assess the risk of severe adverse reactions. The vaccine's effectiveness is based on immune response data, and confirmatory clinical studies will be conducted.
- FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus FDA.gov
- FDA approves first vaccine against chikungunya virus CNN
- US approves first vaccine against chikungunya virus: drug regulator Bangkok Post
- Chikungunya virus: FDA OKs first vaccine for people 18 years or older USA TODAY
- US FDA approves Valneva's chikungunya vaccine Reuters
Reading Insights
0
3
4 min
vs 5 min read
85%
913 → 140 words
Want the full story? Read the original article
Read on FDA.gov